176 related articles for article (PubMed ID: 21118038)
1. Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Boren TP; Miller DS
Womens Health (Lond); 2010 Nov; 6(6):789-95. PubMed ID: 21118038
[TBL] [Abstract][Full Text] [Related]
2. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
[TBL] [Abstract][Full Text] [Related]
3. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
[TBL] [Abstract][Full Text] [Related]
4. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.
Bozas GT; Bamias A; Kastritis E; Rodolakis A; Vlahos G; Papadimitriou CA; Markaki S; Dimopoulos MA
Eur J Gynaecol Oncol; 2005; 26(6):627-31. PubMed ID: 16398224
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy of uterine clear cell carcinoma: a review.
Xu Y; Hanna RK; Elshaikh MA
Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
8. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
Creasman WT; Kohler MF; Odicino F; Maisonneuve P; Boyle P
Gynecol Oncol; 2004 Dec; 95(3):593-6. PubMed ID: 15581969
[TBL] [Abstract][Full Text] [Related]
10. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.
Vandenput I; Trovik J; Vergote I; Moerman P; Leunen K; Berteloot P; Neven P; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):332-6. PubMed ID: 21270614
[TBL] [Abstract][Full Text] [Related]
11. Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy.
Chang-Halpenny CN; Natarajan S; Hwang-Graziano J
Gynecol Oncol; 2013 Dec; 131(3):598-603. PubMed ID: 24135679
[TBL] [Abstract][Full Text] [Related]
12. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
Vaidya AP; Littell R; Krasner C; Duska LR
Int J Gynecol Cancer; 2006; 16 Suppl 1():267-72. PubMed ID: 16515602
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
14. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
15. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
Fader AN; Drake RD; O'Malley DM; Gibbons HE; Huh WK; Havrilesky LJ; Gehrig PA; Tuller E; Axtell AE; Zanotti KM;
Cancer; 2009 May; 115(10):2119-27. PubMed ID: 19306417
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced-stage and recurrent endometrial cancer.
Ray M; Fleming G
Semin Oncol; 2009 Apr; 36(2):145-54. PubMed ID: 19332249
[TBL] [Abstract][Full Text] [Related]
17. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
[TBL] [Abstract][Full Text] [Related]
19. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.
Fader AN; Boruta D; Olawaiye AB; Gehrig PA
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):21-9. PubMed ID: 19952744
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for patients with stage I papillary serous endometrial cancer.
Alobaid A; Bruchim I; Verkooijen H; Gauthier P; Petignat P
Eur J Surg Oncol; 2006 Apr; 32(3):358-62. PubMed ID: 16414233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
